In this study, we have compared resistance to insulin-mediated glucose disposal and plasma concentrations of nitric oxide (NO) and cyclic-GMP in healthy volunteers with (n ϭ 35) or without (n ϭ 27) at least one sibling and one parent with type 2 diabetes. The 62 volunteers were further divided into groups of those with normal glucose tolerance or impaired glucose tolerance. Insulin-mediated glucose disposal was quantified by determining the insulin sensitivity index (ISI) in response to a low-dose, constant infusion of insulin (25 mU/kg⅐h) and glucose (4 mg/kg⅐min) for 150 min. The mean (ϮSEM) ISI [(mL kg Ϫ1 min Ϫ1 /pmol/L) ϫ 10 3 ] was significantly greater in those without a family history (30.3 Ϯ 2.3) as compared with nondiabetic volunteers with a family history of type 2 diabetes, whether they had normal glucose tolerance (17.0 Ϯ 7.2) or impaired glucose tolerance (9.5 Ϯ 1.4). In addition, basal NO levels, evaluated by the measurement of its stable end products [i.e. nitrite and nitrate levels (NO 2 Ϫ/
T HE RELATIONSHIP between nitric oxide (NO) and resistance to insulin-mediated glucose disposal is clearly controversial. For example, there is evidence that endothelial NO synthesis and insulin sensitivity are positively correlated in healthy volunteers (1) . This physiological effect could well be mediated by the apparent ability of insulin to increase NO release, accounting for the vasodilatory effects of insulin (2, 3) . The insulin-mediated vasodilatory response is decreased in obese individuals and patients with type 2 diabetes (4, 5) , situations known to be associated with insulin resistance (6 -8) . Based on these data, it could be argued that a decrease in the ability of insulin to increase endothelial NO release prevents insulin-mediated vasodilation, resulting in muscle insulin resistance.
Unfortunately, not all published data are consistent with the formulation outlined above. For example, there is evidence that NO production may be normal or actually is increased in patients and/or animal models of type 2 diabetes (9 -12). However, not all studies have confirmed this finding, and it is possible that elevated NO concentrations only occur in patients with type 2 early in the disease, at a time when vascular complications are absent (13, 14) .
The present study was initiated in an effort to examine the relationship between NO and insulin resistance in a somewhat different fashion; namely, by focusing on healthy volunteers, without known vascular disease or manifest hyperglycemia, but likely to differ in their degree of insulin resistance. For this purpose, we enrolled healthy volunteers with or without a family history of type 2 diabetes. The participants with a positive family history had at least one sibling and one parent with a diagnosis of type 2 diabetes. In addition to quantifying their degree of insulin resistance and NO concentrations, we also determined concentrations of cyclic-GMP.
Materials and Methods
The study population consisted of 62 nondiabetic individuals of Caucasian ancestry, living in Northern Italy. Thirty-five of the subjects had at least one sibling and one parent with type 2 diabetes, whereas 27 individuals were without a family history of type 2 diabetes. Of the 35 individuals with a family history of type 2 diabetes, 14 had impaired glucose tolerance (IGT) and 21 were normal glucose tolerant (NGT) by WHO criteria (15) . Participants were normotensive, nonsmokers, without history of ischemic heart disease, and a normal resting electrocardiogram; the clinical characteristics of the three groups are shown in Table 1 . It can be seen that individuals with a family history of type 2 diabetes, who also had IGT, had higher values for both body mass index and ratio of waist to hip girth. There was no other significant differences between the three groups.
Samples for NO, cyclic-GMP, glucose, insulin, triglyceride, cholesterol, and high-density lipoprotein (HDL)-cholesterol concentrations were obtained after at least 15 min in a supine position after an overnight fast. Blood pressure was taken in the recumbent position after 10 min of rest, using a random zero sphygmomanometer, and the mean of the two measurements was used as the value. Blood was also drawn 120 min after a 75-g oral glucose challenge for measurement of glucose and insulin concentrations.
Insulin-mediated glucose disposal was determined by means of the low-dose insulin glucose infusion test (LDIGIT) (16) . This approach is based on determining the steady-state plasma glucose (SSPG) and steady-state plasma insulin (SSPI) concentrations in response to a continuous low-dose infusion of insulin (25 mU/kg⅐h) and glucose (4 mg/ kg⅐min) for 150 min. Samples for blood glucose and insulin determinations were taken at Ϫ5, 0, 10, 20, 30, 40, 50, 60, 90, 120, and every 5 min until 150 min. Because hepatic glucose production is completely suppressed, the insulin sensitivity index (ISI) was calculated by dividing the constant glucose infusion rate by the SSPI concentration during the last 30 min of each test and normalizing this ratio to the SSPG concentration in the same period (16) .
All subjects kept a diary of food intake for 3 days before measurement of NO and cyclic-GMP to control for differences in food intake. Because nitrogen intake could influence the measurement of NO 2 Ϫ/NO 3 Ϫ levels (17), the amount of nitrogen consumed was calculated. This precaution was taken despite the fact that the half-life of nitrate, a major component of the end product of NO, is 3 h (18) and 12 h of overnight fast and should be sufficient to result in total clearance of nitrogen dietary intake. No differences were found in the daily energy intake of the three groups of subjects, for either total amount of calories consumed or the proportion of calories as carbohydrate, lipid, or protein. Furthermore, because animal and vegetable nitrogen daily intakes were identical in the three groups of subjects, it is unlikely that variations in any of these variables would influence the measurement of NO 2 Ϫ/NO 3 Ϫ levels. Finally, any systematic error should have affected all groups to a similar extent.
Plasma glucose was measured with a glucose-oxidase based method (Unimate 5 Glucose HK; Roche, Basel, Switzerland). Serum triglyceride (intra-assay, 1.7%; interassay 9.7%), total cholesterol, and HDL-cholesterol levels (intra-assay, 3.5%; interassay 8.8%) were measured using automated enzymatic spectrophotometric techniques adapted to Cobas Fara II (Roche). Quality control was assessed by examining systematic and random error on pooled sera at low and high levels. Serum insulin levels [intra-assay coefficient of variation (CV), 3.0%; interassay CV, 5.0%] were assayed with a Microparticle Enzyme Immunoassay (MEIA, IMX; Abbott Laboratories, Abbott Park, IL) in which the lowest insulin sensitivity is 6 pmol/L. Cross-reactivity with the measurement of proinsulin is less than 2%. Serum C-peptide levels (intra-assay CV, 3.0%; interassay CV, 3.0%) were assayed by RIA using commercial kits (Medical System, Genova, Italy). Serum creatinine levels were assayed by using a spectrophotometric automated method on Cobas Fara II (Crea Unimate 5; Roche). Cyclic-GMP was assayed with a RIA kit (Amersham International, Buckinghamshire, UK), and NO levels were assayed by measurement of the end products of their metabolism [i.e. nitrite and nitrate levels (NO 2 Ϫ/NO 3 Ϫ)], using enzymatic catalysis coupled with Griess reaction. Specifically, NO 3 Ϫ was reduced to NO 2 Ϫ by 0.1 U nitrate reductase, 5 ϫ 10 Ϫ6 M flavin adenine dinucleotide, and 250 ϫ 10 Ϫ6 M nicotinamide adenine dinucleotide phosphate (reduced form). Samples were incubated at 37C for 3 h, 8.8 U lactate dehydrogenase and 10 Ϫ2 M pyruvate were added to each well, and the sample was incubated for 90 min at 37C. Finally, Griess reactives were added to each well, and the sample was read at 540 nm (19) .
Statistical analysis
Results are expressed as mean Ϯ sem. Comparisons between groups were performed using one-way ANOVAs, followed by Scheffe-F test when appropriate. Relationships between different variables were analyzed by Pearson correlations. Statistical significance was accepted at the P ϭ 0.05 level.
Results
The metabolic characteristics of the three groups are shown in Table 2 . By definition, the plasma glucose concentration was higher 120 min after 75 g oral glucose in those with IGT as compared with the other two groups. In addition, this group had significantly higher insulin concentrations, both fasting and postglucose load, as well as higher triglyceride concentrations.
The results of the LDIGIT are shown in Table 3 and Fig. 1 . The SSPG concentrations were significantly higher in those with IGT as compared with other two groups. In addition, the SSPG concentrations were higher in the NGT group with a family history of type 2 diabetes than in those without a family history. It should be emphasized that the higher SSPG concentrations were achieved despite the fact that the SSPI concentrations were also higher in those with a positive family history. This phenomenon is most likely the result of a failure to inhibit endogenous insulin secretion in these individuals, as attested to by their much higher C-peptide concentrations during the infusion. To compensate for the differences in SSPI, the ISI was calculated, and Table 3 shows that the ISI was lower in both groups with a positive family history of type 2 diabetes (i.e. they were more insulin resistant than those with a negative family history). Values for concentrations of NO 2 Ϫ/NO 3 Ϫ and cyclic-GMP are given in Table 4 . It can be seen that concentrations of NO 2 Ϫ/NO 3 Ϫ were higher and cyclic-GMP lower in both groups with a family history of type 2 diabetes. Furthermore, these values did not seem to differ as a function of glucose tolerance in those with a family history.
The analysis to this point has focused on group comparisons. However, because insulin resistance, glucose tolerance, and insulin responses to oral glucose were distributed continuously, we thought it useful to consider the relationships between insulin resistance and plasma insulin response to glucose to the other relevant variables in the entire population of 62 volunteers. Fig. 2 illustrates the Pearson correlation coefficients between the ISI and the metabolic variables listed in Table 2 . These results demonstrate that the more insulin resistant (lower ISI), the higher triglyceride and NO 2 Ϫ/NO 3 Ϫ concentration and the lower the cyclic-GMP concentration. The relationships between the ISI and glucose and HDL-cholesterol concentrations were not statistically significant.
Because the insulin concentration 120 min after oral glucose was highly correlated with the ISI (r ϭ Ϫ0.69, P Ͻ 0.001), we also calculated the relationship between the insulin response and the variables listed in Table 2 . The correlation coefficients between the 120-min insulin response and both plasma triglyceride (r ϭ 0.47, P Ͻ 0.001) and NO 2 Ϫ/NO 3 Ϫ (r ϭ 0.39, P Ͻ 0.001) concentration remained highly significant (data not shown). However, the relationship between insulin response and cyclic-GMP was somewhat lower (r ϭ Ϫ0.22, P ϭ 0.08), whereas that between insulin response and both triglyceride (r ϭ 0.47, P Ͻ 0.001) and HDL-cholesterol (r ϭ Ϫ0.31, P Ͻ 0.02) increased.
Discussion
The most straight-forward result of the current study is that nondiabetic individuals with a positive family history of type 2 diabetes are insulin resistant, with higher plasma NO concentrations, than are healthy volunteers without a family history of diabetes. This finding was observed when comparisons were made between the three experimental groups, as well as when the relationship between insulin sensitivity and plasma NO concentrations was defined in the 62 healthy volunteers who made up the study population. On the other hand, although the conclusion that plasma NO is higher in insulin-resistant, nondiabetic volunteers is consistent within the present study, it seems to be at odds with considerable published data. Given the apparent disparity between experimental results, it seems reasonable to begin the discussion by focusing on possible explanations for the apparent discrepancy.
The study most similar to our present study is that of Petrie et al. (1) , who measured insulin-mediated glucose disposal in 19 healthy volunteers with the hyperinsulinemic, euglycemic clamp technique and defined the relationship between this value and an estimate of NO production based on the forearm vasoconstrictor responses to Ng-monomethyl-l-arginine. On the basis of these measurements, they concluded that endothelial NO synthesis and insulin sensitivity are positively related in healthy volunteers (i.e. the more insulin sensitive, the greater the NO synthesis). One obvious difference between the results of the two studies is the method of assessing insulin sensitivity: the clamp vs. the LDIGIT method. However, this difference seems unlikely to account for the disparity for at least two reasons. First, there is evi- dence that values of insulin resistance obtained with the two methods are significantly correlated (16) . Second, the ISI and insulin response to oral glucose were also highly correlated (r ϭ Ϫ0.69, P Ͻ 0.001), a relationship very similar to that described in a nondiabetic population between specific estimates of insulin resistance and insulin response to glucose (20, 21) . The two reports also differ in the methods used to quantify NO production; a chemical estimate in the current study, as compared with a functional assay based on the vasodilatory response to inhibition of NO synthesis. The chemical estimate we used as an index of NO production involved measurement of NO 2 Ϫ/NO 3 Ϫ, stable degradation products of NO in biological solutions, and there is evidence that NO 2 Ϫ/NO 3 Ϫ serves as an accurate indicator of NO production in vivo (18, 22) . The method used by Petrie et al. (1) to assess NO production is a functional assay, dependent on inhibition of enzyme responsible for the generation of NO and the ability of the endothelium to respond to the change in NO production. As such, it is possible that the insulin-resistant patients studied by Petrie et al. (1) did not have a defect on NO production, but rather an abnormal endothelial response to NO. In other words, it is the biological effect of NO, not its production, that is abnormal in insulin-resistant subjects.
It is currently believed that NO interacts with soluble guanylate cyclase, leading to elevation of cyclic-GMP concentrations (22, 23) , and Albert et al. (24) have recently shown that inhaled NO produced a 3-fold elevation in plasma cyclic-GMP concentrations. Given evidence that cyclic-GMP concentrations are increased in response to NO and the view that cyclic-GMP is the effector messenger of NO, it becomes possible to reconcile apparently conflicting data. The results of this study demonstrated that cyclic-GMP concentrations were lower in both groups of subjects with a family history of type 2 diabetes. A simple approach to the relationship between the ISI, NO, and cyclic-GMP is to propose that insulin resistance is associated with an impairment in the ability of NO to generate its messenger (cycling-GMP), leading to a decrease in cyclic-GMP generation and a relative decline in the ability of insulin to produce vasodilation. The increase in NO 2 Ϫ/NO 3 Ϫ associated with insulin resistance could then represent an effort to compensate for the defect in cyclic-GMP production. This hypothesis is consistent with the results of an earlier study from our laboratory, showing that insulin-resistant subjects with metabolic Syndrome X had higher plasma concentrations of NO, both in the basal state and in response to insulin stimulation as compared with an insulin-sensitive control group (25) . However, despite the higher levels of NO, insulin-stimulated vasodilation was impaired in those with the metabolic Syndrome X. Thus, in this instance, insulin-induced vasodilation was blunted in insulin-resistant subjects, not because of an inability to produce NO, but rather due to an inhibition of NO action presumably secondary to the generation of cyclic-GMP. Although quite speculative, this formulation is consistent with the current results, the conclusion by Petrie et al. (1) of a relationship between insulin resistance and the endothelial response to inhibition of NO synthesis, as well as the evidence that the vasodilatory response to insulin is decreased in insulinresistant individuals (4, 5). In conclusion, the results presented are consistent with the hypothesis that plasma NO concentrations are higher than normal in insulin-resistant individuals and the defect in insulin-mediated vasodilation in these individuals is secondary to a defect in the generation of the effector molecule cyclic-GMP. On the other hand, it is important to emphasize that the situation is certainly more complex. For example, our laboratory (25) has also shown that although individuals with the cardiac Syndrome X are relatively insulin resistant compared with the control group, their basal NO concentrations were similar to control values and did not increase in response to insulin. However, these subjects also had a blunted vasodilatory response to insulin. Obviously, the cause of the blunted vasodilatory response in those with cardiac Syndrome X cannot be the same as individuals with the metabolic Syndrome X. One explanation for this disparity is the suggestion by Egashira et al. (26) that impaired vasodilation in patients with cardiac Syndrome X is due to a defect in NO synthesis. The fact that NO levels were not increased in these subjects may be because the degree of insulin resistance was not severe as that in those with the metabolic Syndrome X. In support of this hypothesis is that individuals with cardiac Syndrome X also had a normal value for insulin-stimulated glucose storage.
Finally, it must be emphasized that our conclusion that NO production is increased in insulin-resistant subjects is not the only interpretation of our results. For example, higher NO concentrations in insulin-resistant subjects could be due to decreased excretion, rather than increased production of NO. Similarly, even if it is assumed that increased production is the cause of higher NO 2 Ϫ/NO 3 Ϫ levels, it is possible that this was due to stimulation of NO production in noninsulinsensitive tissues (e.g. liver or kidney). Finally, there may be an increase in the catabolic rate of cyclic-GMP in insulinresistant subjects, and the lower cyclic-GMP concentrations need not be due to an impairment in the ability of NO to generate the messenger. Obviously, these issues must be clarified to substantiate our suggestion that NO production is increased in insulin-resistant individuals and that the impaired endothelial function described by others (1, 4, 5, 27, 28) in these individuals is due to a defect in the generation of cyclic-GMP by NO.
